{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:30:29Z","timestamp":1794475829428,"version":"4.9.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001849","name":"Defence Research and Development Organisation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024215","name":"ICMR- National Institute of Virology","doi-asserted-by":"publisher","award":["HIV-1 pNL4-3"],"award-info":[{"award-number":["HIV-1 pNL4-3"]}],"id":[{"id":"10.13039\/501100024215","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023171","name":"Life Sciences Research Board","doi-asserted-by":"publisher","award":["LSRB\/o1\/15 001\/LSRB-422 \/BTB \/2023"],"award-info":[{"award-number":["LSRB\/o1\/15 001\/LSRB-422 \/BTB \/2023"]}],"id":[{"id":"10.13039\/501100023171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007780","name":"Indian Institute of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["ICMR\/DHR\/NOHM\/SN-ID-2\/2025\/04\/02"],"award-info":[{"award-number":["ICMR\/DHR\/NOHM\/SN-ID-2\/2025\/04\/02"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007334","name":"Ministry of Health and Family Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020622","name":"Translational Health Science and Technology Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128682","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T12:02:26Z","timestamp":1778328146000},"page":"128682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative immunogenicity of monomeric and tetrameric Nipah virus G glycoprotein-based vaccine candidates demonstrate robust antibody responses in both forms"],"prefix":"10.1016","volume":"84","author":[{"given":"Surbhi","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurleen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil A.","family":"Baby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangita Kumari","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya Mangala","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas Dhar","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubbir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweety","family":"Samal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128682_bb0005","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02405-1","article-title":"Projecting vaccine demand and impact for emerging zoonotic pathogens","volume":"20","author":"Lerch","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2026.128682_bb0010","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/1747493018778713","article-title":"Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke","volume":"13","author":"Sacks","year":"2018","journal-title":"Int J Stroke"},{"key":"10.1016\/j.vaccine.2026.128682_bb0015","doi-asserted-by":"crossref","DOI":"10.3201\/eid2309.161922","article-title":"Convergence of humans, bats, trees, and culture in Nipah virus transmission, Bangladesh","volume":"23","author":"Gurley","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128682_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/01652176.2019.1580827","article-title":"Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies\u2013a comprehensive review","volume":"39","author":"Singh","year":"2019","journal-title":"Vet Q"},{"key":"10.1016\/j.vaccine.2026.128682_bb0025","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.288.5470.1432","article-title":"Nipah virus: a recently emergent deadly paramyxovirus","volume":"288","author":"Chua","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128682_bb0030","article-title":"Nipah virus detection at bat roosts after spillover events, Bangladesh, 2012\u20132019","volume":"28","author":"CD","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128682_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003926","article-title":"Pandemic potential of the Nipah virus and public health strategies adopted during outbreaks: lessons from Kerala, India","volume":"4","author":"Anish","year":"2024","journal-title":"PLoS Glob Public Health"},{"key":"10.1016\/j.vaccine.2026.128682_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ani13010159","article-title":"Nipah virus disease: epidemiological, clinical, diagnostic and legislative aspects of this unpredictable emerging zoonosis","volume":"13","author":"Bruno","year":"2022","journal-title":"Animals"},{"key":"10.1016\/j.vaccine.2026.128682_bb0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/v12040465","article-title":"Nipah virus: past outbreaks and future containment","volume":"12","author":"Soman Pillai","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128682_bb0050","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00128-23","article-title":"Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics","volume":"38","author":"Spengler","year":"2025","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2026.128682_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007393","article-title":"Prioritizing surveillance of Nipah virus in India","volume":"13","author":"Plowright","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128682_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010658","article-title":"Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: model for assessment of live vaccines with neurotropic potential","volume":"18","author":"Monath","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2026.128682_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1031523","article-title":"Assessment of the immunogenicity and protection of a Nipah virus soluble G vaccine candidate in mice and pigs","volume":"13","author":"Gao","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2026.128682_bb0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41541-025-01319-2","article-title":"Antigenic landscape of Nipah virus attachment glycoprotein analysis reveals a protective immunodominant epitope across species","volume":"11","author":"Zhou","year":"2026","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128682_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/v17111429","article-title":"Establishment of a VSV-based pseudovirus platform for in vitro and in vivo evaluation of Nipah vaccine-induced neutralizing responses","volume":"17","author":"Bae","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128682_bb0080","unstructured":"O'Leary K. A much-needed vaccine for Nipah virus. Nat Med."},{"key":"10.1016\/j.vaccine.2026.128682_bb0085","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/S0140-6736(25)02277-9","article-title":"Safety and immunogenicity of the Hendra virus recombinant soluble glycoprotein G Nipah virus vaccine in adults","volume":"406","author":"Yadav","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128682_bb0090","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/S0140-6736(25)01390-X","article-title":"Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study","volume":"406","author":"Frenck","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128682_bb0095","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.1073\/pnas.0804797105","article-title":"Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3","volume":"105","author":"Xu","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2026.128682_bb0100","doi-asserted-by":"crossref","first-page":"10652","DOI":"10.1073\/pnas.0504887102","article-title":"Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus","volume":"102","author":"Bonaparte","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2026.128682_bb0105","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/JVI.78.2.834-840.2004","article-title":"Nipah virus: vaccination and passive protection studies in a hamster model","volume":"78","author":"Guillaume","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128682_bb0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00430-022-00760-7","article-title":"Intrinsic D614G and P681R\/H mutations in SARS-CoV-2 VoCs alpha, Delta, omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity","volume":"212","author":"Khatri","year":"2023","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2026.128682_bb0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/22221751.2019.1571871","article-title":"Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities","volume":"8","author":"Nie","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2026.128682_bb0120","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10529-023-03351-5","article-title":"Establishment of a neutralization assay for Nipah virus using a high-titer pseudovirus system","volume":"45","author":"Luo","year":"2023","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.vaccine.2026.128682_bb0125","doi-asserted-by":"crossref","first-page":"25057","DOI":"10.1073\/pnas.1912503116","article-title":"A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex","volume":"116","author":"Avanzato","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2026.128682_bb0130","doi-asserted-by":"crossref","first-page":"18256","DOI":"10.1038\/s41598-020-75056-y","article-title":"Prediction of the binding interface between monoclonal antibody m102. 4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking","volume":"10","author":"Tit-Oon","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128682_bb0135","doi-asserted-by":"crossref","first-page":"2501996","DOI":"10.1002\/advs.202501996","article-title":"Potent cross-neutralizing antibodies reveal vulnerabilities of Henipavirus fusion glycoprotein","volume":"12","author":"Ren","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.vaccine.2026.128682_bb0140","doi-asserted-by":"crossref","first-page":"29a","DOI":"10.1016\/j.bpj.2021.11.2562","article-title":"Architecture and antigenicity of the Nipah virus attachment glycoprotein","volume":"121","author":"Wang","year":"2022","journal-title":"Biophys J"},{"key":"10.1016\/j.vaccine.2026.128682_bb0145","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.cell.2020.11.023","article-title":"Potent henipavirus neutralization by antibodies recognizing diverse sites on Hendra and Nipah virus receptor binding protein","volume":"183","author":"Dong","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128682_bb0150","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41392-025-02370-0","article-title":"Single amino acid substitution in Hendra virus attachment glycoprotein induces cross-neutralizing antibodies against Nipah virus","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2026.128682_bb0155","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/S0006-3495(02)75302-2","article-title":"Differences in electrostatic properties at antibody\u2013antigen binding sites: implications for specificity and cross-reactivity","volume":"83","author":"Sinha","year":"2002","journal-title":"Biophys J"},{"key":"10.1016\/j.vaccine.2026.128682_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.9.1.7821765","article-title":"Structural features of the reactions between antibodies and protein antigens","volume":"9","author":"Braden","year":"1995","journal-title":"FASEB J"},{"key":"10.1016\/j.vaccine.2026.128682_bb0165","series-title":"Immunobiology: The immune system in health and disease","article-title":"The interaction of the antibody molecule with specific antigen","author":"Janeway","year":"2001"},{"key":"10.1016\/j.vaccine.2026.128682_bb0170","doi-asserted-by":"crossref","first-page":"101477","DOI":"10.1016\/j.eclinm.2022.101477","article-title":"Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (trimer 4571) vaccine in healthy adults: a first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial","volume":"48","author":"Houser","year":"2022","journal-title":"EClinical Medicine"},{"key":"10.1016\/j.vaccine.2026.128682_bb0175","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.128682_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128682_bb0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/vaccines1040497","article-title":"Envelope glycoprotein trimers as HIV-1 vaccine immunogens","volume":"1","author":"Sattentau","year":"2013","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128682_bb0190","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-8-48","article-title":"A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells","volume":"8","author":"Melchers","year":"2011","journal-title":"Retrovirology"},{"key":"10.1016\/j.vaccine.2026.128682_bb0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12275-023-00021-z","article-title":"Recombinant protein mimicking the antigenic structure of the viral surface envelope protein reinforces induction of an antigen-specific and virus-neutralizing immune response against dengue virus","volume":"61","author":"Kim","year":"2023","journal-title":"J Microbiol"},{"key":"10.1016\/j.vaccine.2026.128682_bb0200","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","article-title":"Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19\/AZD1222 vaccine","volume":"7","author":"Watanabe","year":"2021","journal-title":"ACS Central Sci"},{"key":"10.1016\/j.vaccine.2026.128682_bb0205","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41467-017-01549-6","article-title":"Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding","volume":"8","author":"Kulp","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128682_bb0210","article-title":"Highly scalable prefusion-stabilized RSV F vaccine with enhanced immunogenicity and robust protection","volume":"16","author":"Huang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128682_bb0215","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1016\/j.vaccine.2011.06.015","article-title":"A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge","volume":"29","author":"Pallister","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128682_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004241","article-title":"A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge","volume":"4","author":"Bossart","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128682_bb0225","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.vetmic.2018.03.031","article-title":"Formation of high-order oligomers is required for functional bioactivity of an African bat henipavirus surface glycoprotein","volume":"218","author":"Behner","year":"2018","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2026.128682_bb0230","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41541-024-00954-5","article-title":"An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection","volume":"9","author":"Zhou","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128682_bb0235","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/14760584.2025.2476523","article-title":"Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response","volume":"24","author":"Kim","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128682_bb0240","article-title":"Nipah virus vaccines evaluated in pigs as a \u2018one Health\u2019approach to protect public health","volume":"10","author":"RK","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128682_bb0245","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/tmi.13979","article-title":"Current progress towards prevention of Nipah and Hendra disease in humans: a scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials","volume":"29","author":"Rodrigue","year":"2024","journal-title":"Trop Med Int Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:00:53Z","timestamp":1794474053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":49,"alternative-id":["S0264410X26004901"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128682","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative immunogenicity of monomeric and tetrameric Nipah virus G glycoprotein-based vaccine candidates demonstrate robust antibody responses in both forms","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128682"}}